With the desire to contribute to raising awareness of pregnant women in screening for birth defects in children and accompanying obstetricians to make NIPT the first prenatal screening test for pregnant women, popularizing the method. NIPT birth defect screening method, on April 25, 2024, Gene Solutions Lab Co., Ltd. coordinated with the Ben Tre Provincial Center for Disease Control (CDC) to sign a memorandum of understanding, implementing the “Society” program. NIPT testing for all pregnant women, improving the quality of the Vietnamese population.”
Mr. Nguyen Van Thuan – Deputy Sales Director of Gene Solutions Company spoke at the contract signing ceremony
Accordingly, pregnant women in the first trimester of pregnancy when participating in the program are supported with counseling and performing one of two types of NIPT tests – triSureFirst or triSure Thalass. The test will screen for common chromosomal abnormalities in the fetus including Down syndrome, Edwards syndrome, Patau, Turner syndrome and integrate screening for Thalassemia according to the target program. national population.
In case the pregnant woman has a positive test result, she will be advised and given amniocentesis/chorionic villus biopsy to diagnose the pregnant woman. Gene Solutions will support part of the funding. The program will run from now until June 10, 2024 and may end early if free samples run out.
Overview of the scientific conference on “Updating the application of genetic testing in prenatal screening and diagnosis”.
At the signing ceremony, Gene Solutions Co., Ltd. jointly organized a scientific conference on “Updating genetic testing applications in prenatal screening and diagnosis”. Thereby helping obstetric staff update the application of genetic testing in prenatal screening and diagnosis, the practical benefits of the NIPT test integrated with Thalassemia screening, contributing to bringing this method to pregnant women quickly. more effectively, aiming to improve the quality of the Vietnamese population.
